Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 438

Similar articles for PubMed (Select 14872180)

1.

Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.

Bergen R, Black S, Shinefield H, Lewis E, Ray P, Hansen J, Walker R, Hessel C, Cordova J, Mendelman PM.

Pediatr Infect Dis J. 2004 Feb;23(2):138-44.

PMID:
14872180
2.

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.

Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP.

Pediatrics. 2005 Sep;116(3):e397-407.

3.

Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children.

Piedra PA, Yan L, Kotloff K, Zangwill K, Bernstein DI, King J, Treanor J, Munoz F, Wolff M, Cho I, Mendelman PM, Cordova J, Belshe RB.

Pediatrics. 2002 Oct;110(4):662-72.

PMID:
12359778
4.
5.

Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.

Vesikari T, Karvonen A, Smith HM, Dunning A, Razmpour A, Saville MK, Gruber WC, Forrest BD.

Pediatrics. 2008 Mar;121(3):e568-73. doi: 10.1542/peds.2007-1405. Epub 2008 Feb 25.

6.

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B; CAIV-T Asthma Study Group.

Pediatr Infect Dis J. 2006 Oct;25(10):860-9.

PMID:
17006278
7.

Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children.

Piedra PA.

Semin Pediatr Infect Dis. 2002 Apr;13(2):90-6. Review.

PMID:
12122958
8.

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years.

Belshe RB, Nichol KL, Black SB, Shinefield H, Cordova J, Walker R, Hessel C, Cho I, Mendelman PM.

Clin Infect Dis. 2004 Oct 1;39(7):920-7. Epub 2004 Sep 7.

9.

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.

King JC Jr, Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan L, Newman F, Belshe RB, Kovacs A, Deville JG, Jelonek M; HIV Influenza Study Group.

Pediatr Infect Dis J. 2001 Dec;20(12):1124-31.

PMID:
11740317
10.

Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.

Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD; CAIV-T Study Group.

Pediatr Infect Dis J. 2006 Oct;25(10):870-9.

PMID:
17006279
11.

Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.

Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP.

Pediatrics. 2007 Sep;120(3):e553-64. Epub 2007 Aug 13.

12.
13.

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.

Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P, Treanor J, King J, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, Wolff M.

J Pediatr. 2000 Feb;136(2):168-75.

PMID:
10657821
14.

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.

Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M.

N Engl J Med. 1998 May 14;338(20):1405-12.

15.

Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children.

Gaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kozinetz CA, Riggs MW, Fewlass C, Halloran ME, Longini IM Jr, Glezen WP.

Arch Pediatr Adolesc Med. 2004 Jan;158(1):65-73.

PMID:
14706961
16.

Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.

Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD; Pan-Asian CAIV-T Pediatric Efficacy Trial Network.

Pediatr Infect Dis J. 2007 Jul;26(7):619-28.

PMID:
17596805
17.

Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities.

Nolan T, Lee MS, Cordova JM, Cho I, Walker RE, August MJ, Larson S, Coelingh KL, Mendelman PM.

Vaccine. 2003 Mar 7;21(11-12):1224-31.

PMID:
12559802
18.

Seasonal influenza vaccines.

Fiore AE, Bridges CB, Cox NJ.

Curr Top Microbiol Immunol. 2009;333:43-82. doi: 10.1007/978-3-540-92165-3_3. Review.

PMID:
19768400
19.

Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma.

Redding G, Walker RE, Hessel C, Virant FS, Ayars GH, Bensch G, Cordova J, Holmes SJ, Mendelman PM.

Pediatr Infect Dis J. 2002 Jan;21(1):44-8.

PMID:
11791098
20.

Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children.

Bernstein DI, Yan L, Treanor J, Mendelman PM, Belshe R; Cold-Adapted, Trivalent, Influenza Vaccine Study Group.

Pediatr Infect Dis J. 2003 Jan;22(1):28-34.

PMID:
12544405
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk